经导管二尖瓣修复与置换:当前真实世界实践的批判性综述
本文综述2009至2025年文献,比较经导管缘对缘修复(TEER)与经导管二尖瓣置换(TMVR)的安全性和疗效。TEER已治疗超过20万例,安全有效但复杂解剖缺乏随机试验证据;TMVR仅超1400例,围术期风险较高且经验有限。两者均需更多高质量研究明确长期结局。
要点
- TEER解剖合适者首选,安全有效且经验丰富。
- TMVR减反流有前景但围术期风险高,需谨慎选患者。
- TMVR技术进步有望减少经心尖入路依赖。
核心结论
- TEER和TMVR是二尖瓣反流治疗的重要进展,但需更多高质量研究明确疗效和长期结局。
- TMVR技术进步可能提升安全性并扩大适用人群。
研究设计与样本
- 对2009年至2025年现有文献进行综合综述,涵盖初始器械试验至最新真实世界研究。
- 采用叙述性综合整合 findings 并评估TMVI现状。
主要发现
- TEER已治疗超过200 000例患者,安全性和有效性确立。
- TMVR已治疗仅超过1400例患者,临床经验更有限。
- TMVR可减少二尖瓣反流但围术期风险更高,需仔细选择患者。
- TEER在复杂解剖中仍缺乏随机试验证据。
关键数值与推荐
- TEER适用于解剖合适的患者,基于严格解剖和临床入选标准的试验获批。
- TMVR需仔细选择患者,围术期风险较高。
临床怎么用
- 解剖合适者优先选择TEER,因其安全有效且经验丰富。
- TMVR应限于谨慎选择的患者,并关注围术期风险。
- 期待TMVR技术进步减少经心尖入路依赖以改善安全性。
局限性
- TEER在复杂解剖中缺乏随机试验证据。
- TMVR临床经验有限,仅超过1400例患者。
- 需更多高质量研究明确长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Transcatheter mitral valve interventions (TMVIs) provide less invasive alternatives for patients deemed ineligible for surgery. This manuscript reviews the evolving landscape of TMVI, limited to a comparative analysis of transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) in terms of safety and efficacy outcomes. METHODS: A comprehensive review of the existing literature was conducted, encompassing data from initial device trials to the most recent real-world studies, ranging from 2009 through 2025. A narrative synthesis was conducted to integrate findings and evaluate the current state of TMVI. RESULTS: Initially approved based on trials with stringent anatomical and clinical inclusion criteria, TEER has been increasingly applied to broader patient populations in real-world settings. Despite its expanded use, there remains a lack of randomized trial evidence for TEER in complex anatomies. TEER remains the preferred option for patients with suitable anatomy, given its well-established safety and efficacy, with over 200 000 patients treated. TMVR demonstrates promise in reducing mitral regurgitation (MR) but is associated with higher periprocedural risks, demands careful patient selection, and is supported by a more limited clinical experience, with just over 1400 patients treated. Emerging technological advancements are anticipated to reduce reliance on transapical access, aiming to improve procedural safety and outcomes. CONCLUSIONS: TEER and TMVR represent significant advancements in the management of MR. However, the field requires additional high-quality studies to clarify the efficacy and long-term outcomes of these interventions. Further technological developments in TMVR may enhance its safety profile and expand its applicability.
引用
- Fiocco A, Besola L, De Carlo M, et al. Transcatheter Mitral Valve Repair and Replacement. A Critical Review of Current Real-World Practice. Eur J Cardiothorac Surg. 2025. PMID: 41148041. doi:10.1093/ejcts/ezaf373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。